

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 January 2023 (12.01.2023)



(10) International Publication Number
WO 2023/281476 A1

(51) International Patent Classification:

C07C 43/23 (2006.01) A61K 31/085 (2006.01)
C07C 215/68 (2006.01) A61K 31/05 (2006.01)
C07C 217/84 (2006.01) A61K 31/09 (2006.01)
C07C 217/66 (2006.01) A61K 31/136 (2006.01)
C07K 7/06 (2006.01) A61K 31/137 (2006.01)

(21) International Application Number:

PCT/IB2022/056358

(22) International Filing Date:

08 July 2022 (08.07.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/219,683 08 July 2021 (08.07.2021) US

(71) Applicants: NEURACLE SCIENCE CO., LTD.

[KR/KR]; 702-2, 145 Anam-ro, Seongbuk-gu, Seoul 02841 (KR). KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION [KR/KR]; 145 Anam-ro, Seonbuk-gu, Seoul 02841 (KR). KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, SEJONG CAMPUS [KR/KR]; 2511, Sejong-ro, Jochi-won-cup, Sejong-si, Seoul 30019 (KR).

(72) Inventors: SEONG, Jae Young; 103-1025, 34, Nowon-ro

22-gil, Nowon-gu, Seoul 01746 (KR). BYUN, Youngjoo; 206-408, 448, Expo-ro, Yuseong-gu, Daejeon 34049 (KR). KWAK, Hoyun; 302-1602, 30, Semi-ro 1-gil, Hanam-si, Gyeonggi-do 12982 (KR). OH, Sitaek; 203-109, 295, Haedeung-ro, Dobong-gu, Seoul 01373 (KR). LEE, Min-Hyeok; 101-306, 52, Wangsan-ro, Dongdaemun-gu, Seoul

02583 (KR). JEONG, Yongwoo; Kyoungilhighlights Villa 302, 76, Nohae-ro 9-gil, Gangbuk-gu, Seoul 01079 (KR). HA, Nui; 131-1904, 135, Gwanak-daero, Dongan-gu, Anyang-si, Gyeonggi-do 13922 (KR). CHO, Eun-Ho; Wise officetel 401, 114, Anam-ro, Dongdaemun-gu, Seoul 02474 (KR). LEE, Suhyun; Aurum Tower 1006, 84, Dong-somun-ro, Seongbuk-gu, Seoul 02846 (KR). LEE, Sang-Myeong; 404-503, 48, Deogyong-daero 697beon-gil, Paldal-gu, Suwon-si, Gyeonggi-do 16435 (KR). LEE, Yerin; Dongdaemun BENEST 516, 92, Wangsan-ro, Dongdaemun-gu, Seoul 02585 (KR). CHO, Eun Bee; Daon building 501, 9, Yangnyeongsi-ro, Dongdaemun-gu, Seoul 02477 (KR). LEE, Jae Keun; 110-101, 197, Seoun-ro, Seocho-gu, Seoul 06608 (KR). KIM, Han-Byul; c/o Neuracle Science Co., Ltd., 702-2, 145 Anam-ro, Seongbuk-gu, Seoul 02841 (KR). KWON, Soon-gu; c/o Neuracle Science Co., Ltd., 702-2, 145 Anam-ro, Seongbuk-gu, Seoul 02841 (KR).

(81) Designated States (unless otherwise indicated, for every


kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: INHIBITORS AND USES THEREOF

FIG. 1A



(57) Abstract: The present disclosure provides mimic molecules that are capable of specifically targeting a FAM19A5 protein, and thereby, inhibiting, reducing, and/or dissociating the interaction between members of the LRR4 protein family and the FAM19A5 protein. The present disclosure also provides methods for promoting neurite outgrowth, by administering a mimic molecule described herein.

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*